Transforming growth factor β is a poor prognostic factor and inhibits the favorable prognostic value of CD8+ CTL in human hepatocellular carcinoma

Journal of Immunotherapy

Volumn 40, Issue 5, 2017, Pages 175-186

  Huang, Chun Yu ^a   Wang, Hua ^a   Liao, Wei ^a   Han, Feng ^a   Li, Yong Qiang ^a   Chen, Shu Wei ^a   Lao, Xiang Ming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CD8+ CTLs; hepatocellular carcinoma; immunosuppression; prognosis; TGF

Indexed keywords

GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; IMMUNOLOGY; LIVER TUMOR; LYMPHOCYTE COUNT; METABOLISM; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; HUMANS; INTERFERON-GAMMA; LIVER NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 85017228568     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000166     Document Type: Article

References (39)

1. Mc-Guire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016; 7: 418-419.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365: 1118-1127.
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115-132.
4. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63: 844-855.
5. Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011; 8: 292-301.
6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883-899.
7. Ungefroren H, Sebens S, Seidl D, et al. Interaction of tumor cells with the microenvironment. Cell Commun Signal. 2011; 9: 1-8.
8. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011; 7: 651-658.
9. Zhu XD, Zhang JB, Zhuang PY, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008; 26: 2707-2716.
10. Ju MJ, Qiu SJ, Fan J, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol. 2009; 131: 498-510.
11. Elsharkawy AM, Mann DA. Nuclear factor-kappa B and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007; 46: 590-597.
12. Wu J, Li J, Salcedo R, et al. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 2012; 72: 3977-3986.
13. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factorbeta regulation of immune responses. Annu Rev Immunol. 2006; 24: 99-146.
14. Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev. 2006; 213: 213-227.
15. Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T-cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005; 8: 369-380.
16. Nemunaitis J, Senzer N, Olivares J, et al. Immune response and survival of refractory cancer patients who received TGF-b2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine. Gene Ther. 2013; 20: 875-879.
17. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T-cell cytotoxicity through TGF beta signals in vivo. Proc Natl Acad Sci USA. 2005; 102: 419-424.
18. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003; 198: 1741-1752.
19. Sprinzl MF, Galle PR. Immune control in hepatocellular carcinoma development and progression: role of stromal cells. Semin Liver Dis. 2014; 34: 376-388.
20. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295: 65-73.
21. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17: 1471-1474.
22. Guasch G, Schober M, Pasolli HA, et al. Loss of TGF beta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell. 2007; 12: 313-327.
23. Yang L, Moses HL. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res. 2008; 68: 9107-9111.
24. Pang Y, Gara SK, Achyut BR, et al. TGF-b signaling in myeloid cells is required for tumor metastasis. Cancer Discov. 2013; 3: 936-951.
25. Reichl P, Haider C, Grubinger M, et al. TGF-beta in epithelial to mesenchymal transition and metastasis of liver carcinoma. Curr Pharm Des. 2012; 18: 4135-4147.
26. Bruna A, Darken RS, Rojo F, et al. High TGF beta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007; 11: 147-160.
27. Giannelli G, Villa E, Lahn M. Transforming growth factor-b as a therapeutic target in hepatocellular carcinoma. Cancer Res. 2014; 74: 1890-1894.
28. Rani B, Cao Y, Malfettone A, et al. Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2014; 20: 4128-4140.
29. Ji F, Fu SJ, Shen SL, et al. The prognostic value of combined TGF-b1 and ELF in hepatocellular carcinoma. BMC Cancer. 2015; 15: 116-126.
30. Li YW, Qiu SJ, Fan J, et al. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol. 2011; 54: 497-505.
31. Brunner SM, Rubner C, Kesselring R, et al. Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology. 2015; 61: 1957-1967.
32. Gorelik L, Flavell RA. Transforming growth factor-beta in Tcell biology. Nat Rev Immunol. 2002; 2: 46-53.
33. Nam JS, Terabe M, Mamura M, et al. An anti-Transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 2008; 68: 3835-3843.
34. Li SX, Tang GS, Zhou DX, et al. Prognostic significance of cytoskeleton-Associated membrane protein 4 and its palmitoyl acyltransferase DHHC2 in hepatocellular carcinoma. Cancer. 2014; 120: 1520-1531.
35. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010; 31: 220-227.
36. Giannelli G, Mikulits W, Dooley S, et al. The rationale for targeting TGF-beta in chronic liver diseases. Eur J Clin Invest. 2016; 46: 349-361.
37. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015; 12: 681-700.
38. Giordano M, Henin C, Maurizio J, et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 2015; 34: 2042-2058.
39. Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGF beta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015; 75: 2232-2242.